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Gestational trophoblastic disease (GTD) is a term that incorporates
a rare but important spectrum of disorders that may complicate
pregnancy. GTD is most commonly associated with an abnormal
conception (either a complete or partial hydatidiform mole or
more rarely choriocarcinoma) but it may follow a normal delivery
or non-molar abortion. Choriocarcinoma following a live birth is
said to have an incidence of 1 in 50 000 births (Bagshawe et al,
1986) and to be associated with a poor prognosis (Bagshaw, 1976;
Tidy et al, 1995; Bower et al, 1997). We have evaluated our expe-
rience in the management of post-partum choriocarcinoma by
undertaking a retrospective analysis of all patients registered and
treated for persistent trophoblastic disease (PTD) between 1987
and 1996 at Weston Park Hospital, specifically identifying those
patients with post-partum choriocarcinoma.
METHODS
The Weston Park Hospital database of gestational trophoblastic
tumours was used to identify all women treated for histologically
confirmed choriocarcinoma. Patients who presented following
full-term non-molar pregnancy had their case notes studied to
identify patient demographics, obstetric history, presentation,
treatment and outcome.
Our current management policy on referral of patients with PTD
is to review and confirm the histological diagnosis of chorio-
carcinoma: the patient undergoes a prognostic risk assessment
including full physical examination, imaging [ultrasound pelvis
and abdomen, computed tomography (CT) thorax, chest X-ray]
and serum b human chorionic gonadotrophin (bhCG) evaluation
prior to initiation of treatment as determined by our modified
Charing Cross prognostic scoring system (Sheridan et al 1993).
Those patients at high risk of central nervous system involvement
also undergo a CT scan of the head and a lumbar puncture
(provided there is no evidence of increased intra-cranial pressure)
to determine the cerebro-spinal fluid:serum bhCG ratio.
RESULTS
Between January 1987 and December 1996, 225 women with PTD
were treated at Weston Park Hospital. Thirty-one patients received
high risk chemotherapy. In nine patients (29%) the antecedent
pregnancy was a full-term non-molar pregnancy. In this group, the
median age was 29 years (range 22–37), and eight of nine women
were multiparous. There was no sexual preponderance in the
antecedent pregnancy (four male, five female).
The time interval from antecedent pregnancy to onset of symp-
toms ranged from 0 to 12 weeks (median 2 weeks). All nine
patients presented with abnormal vaginal bleeding. In four cases
this was persistent from the time of delivery, while in the other five
cases the post-partum haemorrhage commenced at a median of
5 weeks after delivery (range 2–12 weeks). Only two women
experienced lower abdominal pain.
The interval between the antecedent pregnancy and registration
for treatment ranged from 5–25 weeks (median 10 weeks). In one
case 24 weeks elapsed before referral. The patient underwent three
uterine evacuations and only during the final operation was tissue
sent for histological analysis. In a second case, vaginal bleeding
persisted for 3 months from the time of birth, and during this period
the patient received norethisterone and finally presented 17 weeks
post-partum with dyspnoea secondary to multiple pulmonary
metastases. Another case presented at 16 weeks post-partum. She
started bleeding 5 weeks after delivery and underwent a uterine
evacuation at week 7. Despite the histology being reported as
suspicious of choriocarcinoma, the patient went on to receive three
courses of intramuscular medroxyprogesterone acetate before the
appropriate referral was made at 16 weeks post-partum.
By the time of referral seven of nine patients had metastatic
disease. However, these metastases resulted in symptoms in only
two cases: one patient experienced 3 weeks of progressive
dyspnoea; one patient was diagnosed after the death of her
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Correspondence to: BW Hancocknewborn infant at 4 weeks of age due to choriocarcinoma (Picton
et al, 1995). There was no relationship between the time to presen-
tation or referral and the presence of metastases.
All nine patients who presented had high-risk disease, with a
median risk score of 14 (range 10–23). Of note is that the median
level of bhCG at the time of referral was 286 500 iu l–1 (range
93 050–808 500 iu l–1).
All patients received ‘high-risk’ chemotherapy with MAE. This
is an alternating intravenous regimen of methotrexate 300 mg m–2,
with folinic acid rescue, followed by a 7-day rest period and then
dactinomycin (actinomycin D) 0.5 mg day–1 and 3 days of etopo-
side 150 mg m–2 day–1. Treatment was continued until the bhCG
was less than 2 iu l–1 and then continued for a further 8 weeks. In
addition, one patient received high-dose intravenous Methotrexate
(1 g m–2) and intrathecal methotrexate (12.5 mg) for confirmed
cerebral metastases. Another required conversion to second-line
therapy for refractory disease after eight cycles of treatment. She
had a further three courses of chemotherapy with CEC (cisplatin
25 mg m–2 daily for 3 days, etoposide 100 mg m–2 daily for 3 days
and cyclophosphamide 600 mg m–2 for 1 day only, repeated at 7- to
10-day intervals). One patient initially received two courses of
EMA-CO [etoposide, methotrexate, dactinomycin (actinomycin
D), cyclophosphamide, vincristine (Oncovin) (Bower et al, 1997)]
chemotherapy in Australia before returning to this country
where she completed a further six courses of MAE chemotherapy
uneventfully.
Chemotherapy was generally well tolerated. The median
number of cycles of chemotherapy received was eight (range six to
10). Only one patient had a treatment cycle delayed for more than
3 weeks. Six patients exhibited grade III or IV neutropenia and in
three of these neutropenic sepsis resulted. Two patients were given
growth factor (lenograstim) support and two patients had a dose
reduction. Nausea and vomiting were minimal and all patients
exhibited temporary alopecia.
All patients achieved a complete response and remain disease-
free at a median of 5 years (range 2 to 7 years). There was no treat-
ment- or disease-related mortality seen in this group of patients.
All are followed up regularly with urine hCG levels for life.
Future fertility in this patient group does not appear to be
affected. Five women have subsequently had further pregnancies
without complication. Three women have no desire to become
pregnant including one who underwent a hysterectomy during
chemotherapy as her family was complete. The ninth patient has
not had a further pregnancy and her future fertility wishes are not
known. None of our patients has had a subsequent pregnancy
complicated by choriocarcinoma or a hydatidiform mole.
DISCUSSION
Post-partum choriocarcinoma is a very rare complication of
pregnancy with a reported UK incidence of 1 in 50 000 live
births (Bagshawe et al, 1986). The rarity of this condition is
reflected in our own experience. During the study time period we
received nearly 4000 registrations with GTD and managed 225
cases of PTD of whom only nine presented with post-partum
choriocarcinoma.
In our experience, results with multiagent systemic
chemotherapy are excellent and all our patients are alive and well
with no evidence of disease. The Charing Cross Hospital team,
however, has reported from their major experience over 25 years
that choriocarcinoma following a term non-molar pregnancy is an
adverse factor, in both univariate and multivariate analyses. By
reviewing their 272 cases requiring high-risk multiagent
(EMA/CO) chemotherapy they found that 99 cases (36%) of
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Table 1 Summary of findings in nine patients with post-partum choriocarcinoma
Patient A B C D E F G H I
Onset of PV 12 Primary Primary 3 2 6 5 Primary Primary
bleeding (weeks PPH PPH PPH PPH
post-partum)
Diagnosis (weeks 24 7 17 9 7 16 10 7 19
post-partum)
Interval to 12 7 17 6 5 10 5 7 19
diagnosis (weeks)
Number of Multiple Multiple Multiple Multiple Single Multiple Multiple Nil Nil
metastases
Site of Lungs Lungs Lungs Lungs Lungs Lungs Lungs Nil Nil
metastases CNS
Serum bhCG at 258 500 238 500 265 000 286 500 202 500 665 000 808 500 800 000 93 050
diagnosis (iu l–1)
Treatment MAE (10) MAE (8) MAE (8) MAE (9) MAE (8) MAE (7) MAE (7) EMACO (2) MAE (7)
CEC (3) IT MTX MAE (6)
Survival AWNED AWNED AWNED AWNED AWNED AWNED AWNED AWNED AWNED
Duration of 5 4 22766 5 5
follow-up (years)
AWNED, alive and well, no evidence of disease; bhCG, human chorionic gonadotrophin; CEC, cyclophosphamide/etoposide/cisplatin; EMA-CO,
etoposide/methotrexate/actinomycin D (dactinomycin) – cyclophosphamide/Oncovin (vincristine); IT, intrathecal; MAE, methotrexate/actinomycin D
(dactinomycin)/etoposide; MTX, methotrexate; PPH, post-partum haemorrhage; PV, per vaginum.persistent trophoblastic disease followed term pregnancy.
Although our patients are consecutive and recently treated it is
possible that with the number being much smaller (nine patients,
29% of all those requiring high risk chemotherapy) too optimistic
a view was obtained.
Of concern, however, is the time interval/delay between onset of
symptoms and diagnosis with subsequent referral for treatment.
Whilst there are of course a number of possible explanations for
post-partum haemorrhage, many of our patients could have been
referred sooner. Simply sending curettings for histological
analysis, performing a bhCG analysis or having some index of
suspicion if abnormal bleeding per vaginum persists despite thera-
peutic intervention would have led to earlier diagnosis in some
cases. Delays in diagnosis certainly resulted in increased patient
morbidity from choriocarcinoma and may have resulted in more
frequent usage of higher dose multiagent chemotherapy (seven of
nine patients had metastatic disease on referral with a median
bhCG of more than 250 000 iu l–1).
In conclusion, the important message is that although this condi-
tion is extremely uncommon it is potentially treatable and an early
diagnosis is important.
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